GlassScriptPhysician profile
Baron C Atkins
NPI 1841239415
$5,267.35
in general payments reported to CMS, 2019-2025
26 companies · $478 in 2025
The $478 reported for 2025 was more than what 79% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $851 · 2020: $195 · 2021: $22.78 · 2022: $87.89 · 2023: $134 · 2024: $3,499 · 2025: $478.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $3,000 · Food and Beverage: $1,111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $3,000.00 |
| Food and Beverage | $1,110.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,272.87 | 2019-2024 | Da Vinci Surgical System |
| Pfizer INC. | $309.94 | 2019-2025 | |
| Abbvie INC. | $290.01 | 2019-2025 | |
| Biogen, INC. | $207.42 | 2024-2025 | Zurzuvae, Vumerity |
| Lupin INC. | $149.52 | 2019-2020 | |
| Astellas Pharma US INC | $122.34 | 2024-2025 | Veozah |
| Ethicon US, LLC | $106.41 | 2024-2025 | Enseal X1, Vistaseal, Dermabond Prineo |
| Mylan Pharmaceuticals INC. | $91.63 | 2019-2020 | |
| Amag Pharmaceuticals, INC. | $83.92 | 2019-2020 | |
| Vertical Pharmaceuticals, LLC | $67.53 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $62.13 | 2019-2024 | |
| Mayne Pharma Commercial LLC | $60.77 | 2025 | |
| Organon LLC | $55.30 | 2024-2025 | Nexplanon, Nuvaring, Jada System |
| Convatec INC. | $49.56 | 2025 | |
| Shield Therapeutics INC | $48.32 | 2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $44.12 | 2019-2024 | Myosure Tissue Removal Device |
| Avion Pharmaceuticals | $42.17 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $42.01 | 2024 | Myfembree |
| Allergan, INC. | $33.57 | 2019-2020 | |
| Therapeuticsmd, INC. | $22.54 | 2020 | |
| Daiichi Sankyo INC. | $21.17 | 2019 | |
| Exeltis, USA INC. | $18.57 | 2025 | Slynd |
| Coopersurgical, INC. | $18.31 | 2020 | |
| Agile Therapeutics, INC. | $17.02 | 2024 | Twirla |
| Amgen INC. | $16.19 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $14.01 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Baron Atkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.